Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...

EO1001 demonstrates up to ~40-fold greater potency than osimertinib in EGFR ECD-mutant tumor models EO4426 (tezacitabine) demonstrates selective targeting of DNA replication machinery and resistance ...

Cell membranes are more than just barriers—they are dynamic, multifunctional structures essential for life. From controlling ...

BH-501284 demonstrated high potency (median IC50 of 0.83 nM) and prolonged residence time (>54 hours) in KRAS-mutant cell lines, offering ...

New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

New research finds a new strategy for treating a deadly cancer by combining existing drugs to indirectly weaken tumor growth, ...

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...

A study shows that high levels of negatively charged lipids can lock growth receptors into an overactive state, driving ...

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

NSCLC is the most frequent histological subtype of lung cancer, accounting for approximately 85% of patients with lung cancer. NSCLC includes a variety of different lung cancers, most notably ...